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Background: Effect of statin therapy has been reported to be associated with patient’s adherence. Atorvastatin was
available in Japan as a brand-name product beginning in 2000. The first atorvastatin generics were introduced in
Japan in November 2011. The objective of this study was to analyze whether changing from a brand-name
atorvastatin to a generic product would affect patient adherence.
Methods: We conducted a retrospective cohort study that included adult patients who received newly prescribed
brand-name atorvastatin between June 1, 2011 and May 31, 2012, using a health insurance claims database in
Japan. Patients were classified by the presence or absence of changing to a generic during the 6 months from
December 1, 2011 to May 31, 2012 (the index period). The first prescription date for the generic or brand product
during the index period was defined as the index date. Adherence to therapy was assessed by the proportion of
days covered (PDC) and persistence of treatment by time to discontinuation.
Results: There were 135 patients changing to generic atorvastatin and 147 continuing with the brand-name
product. There was no significant difference in decrease of PDC from pre- to post-index date between the changed
cohort and continued cohort (−8.6% vs −10.3%, respectively; P = 0.443). After adjusting for baseline covariates,
including adherence in pre-index date, no statistically significant differences were observed in the adjusted odds of
adherence between the cohorts (adjusted odds ratio = 0.83, 95% confidence interval (CI) = 0.46–1.53). There was also
no significant difference in persistence between two cohorts in the 180-day after post-index date. After analysis of a
Cox proportional hazard regression model controlling for baseline covariates, including adherence in pre-index date,
no statistically significant differences were observed for the hazard of non-persistence between the cohorts
(adjusted hazard ratio = 0.96, 95% CI = 0.60–1.53).
Conclusions: Changing from a brand-name atorvastatin to generic product did not affect adherence for patients
newly treated with atorvastatin.
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The use of generic medicines has been increasing in re-
cent years. Generic medicines are typically 20 to 90%
cheaper than the brand-name equivalent [1]. Therefore,
the substitution of brand-name medicines with generic
equivalents can be a cost containment benefit for pa-
tients. Generic substitution has economic impacts in
healthcare provision, in addition to the potential impact
on the individual. For example, a study by the Generic
Pharmaceutical Association showed that the use of gen-
eric medications in the American health system saved
$239 billion in 2013 alone and generic products have
saved the U.S. economy nearly $1.5 trillion over the past
10 years (2004–2013) [2].
Once a generic product has been approved based on
bioequivalence, therapeutic equivalence is generally as-
sumed. Therefore, there is no difference in safety and effi-
cacy between the generic and original drugs [3]. However,
some studies have reported that patients have concerns
related to generic medicines. Patients felt that generic
medicines did not work as effectively as the original medi-
cine [4,5]. Shrank et al. found that a meaningful propor-
tion of physicians expressed negative perceptions about
generic medications, representing a potential barrier to
generic use [6]. These concerns may result in decreased
confidence in the treatment after generic substitution and
may negatively affect patient’s adherence, which could re-
sult in less-effective treatment.
Atorvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors (statin), which is effective
in reducing low-density lipoprotein cholesterol and cardio-
vascular events [7,8]. It is approved for the treatment of
hyperlipidemia in Japan. Atorvastatin was available in
Japan as a brand-name product beginning in 2000. The
first atorvastatin generics were introduced in Japan in
November 2011. The effect of statin therapy has been re-
ported to be associated with patient’s adherence [9-11].
However, no study has investigated whether changing
from a brand-name atorvastatin to a generic product
affect patient’s adherence.
The objective of this study was to analyze whether chan-
ging from a brand-name atorvastatin to a generic product
would affect adherence in patients newly treated with
atorvastatin using a health insurance claims database.
Methods
Study design and data sources
The study was designed as a retrospective cohort study
using a health insurance claims database covering approxi-
mately 1,000,000 patients from the Japan Medical Data
Center Co. Ltd (JMDC) in Tokyo, Japan [12]. This data-
base provides information on individuals in employment-
based health insurance programs, including demographic
characteristics (eg age, gender), procedures, diagnoses ofdisease coded by International Classification of Disease,
10th Revision (ICD-10), and prescribed drugs (dose, quan-
tity and number of days of supply) from ambulatory and
inpatient care. Drugs are coded according to the Anatom-
ical Classification of Pharmaceutical Products (ATC) of
the European Pharmaceutical Market Research Associ-
ation (EphMRA). The data of each individual can be
tracked in chronological order if multiple medical institu-
tions were used.
Study population
We identified patients (aged ≥18 years) who received
newly prescribed brand-name atorvastatin between June
1, 2011 and May 31, 2012. Newly prescribed patients
were defined as those who did not have a statin pre-
scription in the previous 6 months; prevalent users were
excluded from this study.
The first atorvastatin generics were introduced in Japan
in November 2011. Thus, we considered the presence or
absence of changing to the generics during the 6 months
from December 1, 2011 to May 31, 2012 (index period)
and studied the influence of generics on adherence. The
patients were considered part of the “changed cohort” if
they changed from a brand-name atorvastatin to a generic
product with bioequivalence during index period. The first
prescription date of generic substitution of atorvastatin
was defined as the index date. A change was defined as a
prescription for a generic product within 30 days follow-
ing the last day covered by the brand-name product [13].
During the index period, patients who did not change to a
generic substitute, but continued with the use of the
brand-name drug, were defined as the “continued cohort”;
the index date for this cohort was defined as the first pre-
scription date of the brand-name product during index
period. All patients were continuously enrolled for a mini-
mum of 6 months before and after the index date.
Patients were excluded in this study based on the
following criteria.
1) The patient did not have a prescription for a brand-
name product or did not change from brand-name
to generic product during index period.
2) The patient had missing or invalid dates of
supply or insufficient enrollment in the pre-
index and post-index date.
3) There was a change in dosing schedule.
4) The patient did not meet the definition of changing
(within 30 days).
5) The patient changed to other antihyperlipidemic
agents or other antihyperlipidemic agents were added.
The study protocol was approved by the Institutional
Review Board at International University of Health and
Welfare Ethics Committee.
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Adherence to therapy with atorvastatin was assessed by
the proportion of days covered (PDC) and persistence of
treatment by time to discontinuation.
The PDC was calculated as the number of days’ supply
of medication divided by the number of days in the
follow-up period for each patient [14]. PDC values were
examined before the index date (baseline adherence) and
after the index date. Baseline adherence was calculated
from the first prescription within 180 days before the
index date until the index date. The PDC after the index
date was calculated during the 180-day follow-up period
after index date. The supply for days falling beyond the
180-day study period was truncated and not used in the
PDC calculation. Patients were considered adherent if
PDC ≧ 80% [15]. Persistence was measured as the num-
ber of continuous days from index date to discontinu-
ation in the 180-day [16]. Discontinuation was defined
as a gap of greater than 30 days between medication
supplies [17]. These methods were used in other studies
of adherence [18-20].
Other patient-related variables
The patient variables included age, gender, prescribing
medical establishment (clinic, hospital), type of pre-
scriber (general practitioner, cardiologist, or others),
total number of drugs prescribed, other medications
used for cardiovascular disease, and daily dosage of ator-
vastatin at the index date. Furthermore, comorbidities,
the Charlson comorbidity index [21], which is a useful
measure of comorbidities and health status were deter-
mined during 180 days prior to the index date using
ICD-10 and ATC codes, and other medications for car-
diovascular disease. The duration of use of atorvastatin
prior to the index date was also examined.
Statistical analyses
The demographic and clinical characteristics of patients in
the changed and continued cohorts were compared using
the χ2 test or Fisher’s exact test for categorical variables
and Mann Whitney U test for continuous variables. Differ-
ences in PDC values, which included values before and
after the index date, between the two cohorts were per-
formed using Mann Whitney U test. Differences in PDC
values from pre- to post-index date for the changed and
continued cohorts were performed using paired t tests.
Furthermore, the likelihood of being adherent (PDC ≧
80%) was compared using an unadjusted logistic regression
model, adjusted for baseline covariates, including baseline
adherence (PDC ≧ 80%) and other variables that were sig-
nificantly different between the two cohorts. Crude and ad-
justed odds ratios (OR) and 95% confidence intervals (CI)
were estimated. Differences in persistence values were ana-
lyzed using Mann Whitney U test. Persistence rates wereevaluated using Kaplan-Meier analysis, and the hazard of
non-persistence in the cohorts was compared using a Cox
proportional hazards regression model, adjusted by the
same covariates as above. Crude and adjusted hazard ra-
tios (HR) and 95% CI were estimated. Statistical signifi-
cance was set at P < 0.05 in all analysis. SPSS 20.0 (SPSS
Inc, Chicago, IL) was used for data analyses.
Results
Characteristics of the study population
In the 1,884 new users prescribed brand-name atorva-
statin, there were 308 patients changing from a brand-
name atorvastatin to a generic product during the index
period, and 1,163 patients continuing the brand-name
product during this period. After applying the exclusion
criteria, 135 patients in the changed cohort and 147 pa-
tients in continued cohort were eligible for this study.
Excluded patients of the continued cohort were so much
than the generic cohort because many patients of the
continued cohort did not have valid dates of supply in
the pre- and post-index date (Figure 1).
Baseline characteristics of the study population are
given in Table 1. The gender, age, and type of prescriber
were similar between two cohorts, although there was
significant difference in the prescribing medical estab-
lishment. There was no difference in the overall severity
of comorbidities between the cohorts using the Charlson
comorbidity index. However, the proportion of patients
having hypertension did differ significantly between the
cohorts (52.6% in the changed cohort vs 37.4% in the
continued cohort; P < 0.05) and arrhythmia (0% vs 5.4%,
respectively; P < 0.01). The total number of drugs pre-
scribed was similar in the cohorts, and the use of other
medications for cardiovascular disease was also similar,
except in the proportion of patients treated with calcium
channel blocker was significantly higher in the changed
cohort than that in the continued cohort (22.2% vs 7.5%,
respectively; P < 0.01). Almost all patients in this study
received medications with a daily dosage of 5 mg or
10 mg. The median of duration of use of atorvastatin
was significantly longer in the changed cohort than that
in the continued cohort (126 days vs 98 day, respect-
ively; P < 0.05).
Proportion of patients achieving adherence
Table 2 shows the result of PDC of the two cohorts. In
the pre-index date, the median of PDC value was signifi-
cantly higher in the changed cohort than that in the
continued cohort (97.7% vs 92.4%, respectively; P < 0.01).
The proportion of patients achieving adherence (PDC ≧
80%) was also higher in the changed cohort (85.9% vs
73.5%, respectively; P < 0.05). There was no difference in
the median of PDC value in the post-index date between
the two cohorts. Significant decreases in PDC change
Figure 1 Flow chart of the study cohort.
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ged cohort (−8.6%) and continued cohort (−10.3%).
However, the two cohorts had no statistically significant
difference in PDC change (−8.6% vs −10.3%, respectively;
P = 0.443) (Table 2 and Figure 2). The proportion of pa-
tients achieving adherence (PDC ≧ 80%) in post-index
date was not significantly different (71.1% in the chan-
ged cohort and 63.3% in the continued cohort; P = 0.162;
unadjusted odd ratio [OR] = 1.43; 95% confidence inter-
val [CI] = 0.87–2.36). After adjustment for adherence in
pre-index date (PDC ≧ 80%) and other covariates, such
as patients characteristics and comorbidities at baseline,
no statistically significant differences were observed for
the adjusted odds of adherence between the changed
and continued cohorts (adjusted OR = 0.84, 95% CI =
0.46-1.52).Persistence of treatment
Table 3 shows the persistence of treatment in the two
cohorts. There was no significant difference in persist-
ence duration (time to discontinuation) between the two
cohorts in the 180-day post-index date. Persistence rates
in the two cohorts gradually fell to 75.6% and 67.3%,
respectively, at 180 days and no significant difference
was observed (P = 0.097, Log-rank test; unadjusted
hazard ratio [HR] = 0.69; 95% CI = 0.44–1.08) (Figure 3
and Table 3). After analysis of the Cox proportional
hazard regression model, which controlled for adher-
ence in pre-index date (PDC ≧ 80%), baseline charac-
teristics, and comorbidities, no statistically significant
differences were observed for the hazard of non-
persistence between the changed and continued co-
horts (adjusted HR = 0.97, 95% CI = 0.61–1.55).
Table 1 Baseline characteristics of the study population






Male 78 (57.8) 84 (57.1) 0.914
Female 57 (42.2) 63 (42.9)
Age 53 (27 ~ 73) 52 (25 ~ 72) 0.383
Prescribing medical
establishment
Clinic 83 (61.5) 111 (75.5) <0.05
Hospital 52 (38.5) 36 (24.5)
Type of prescriber
General practitioner 51 (37.8) 59 (40.1)
Cardiologist 5 (3.7) 3 (2.0) 0.841
Others 79 (58.5) 85 (5708)
Comorbidities
Depression 5 (3.7) 9 (6.1) 0.351
Cardiac disease 17 (12.6) 23 (15.6) 0.463
Cerebrovascular
disease
18 (13.3) 15 (10.2) 0.415
Hypertension 71 (52.6) 55 (37.4) <0.05
Diabetes mellitus 63 (46.7) 55 (37.4) 0.116
Cancer 21 (15.6) 22 (15.0) 0.891
Peripheral vascular
disease
10 (7.4) 10 (6.8) 0.844
Arrhythmia 0 8 (5.4) <0.01
Renal dysfunction 1 (0.7) 1 (0.7) 0.729
Dementia 0 1 (0.7) 0.521
Charlson comorbidity
index
1.0 (0 ~ 12) 1.0 (0 ~ 13) 0.698
Total number of
drugs prescribed
3 (1~25) 2 (1~26) 0.870
Other mediation for
cardiovascular disease
inotropic agent 1 (0.7) 2 (1.4) 0.532
Antiarrhythmic agent 1 (0.7) 1 (0.7) 0.729
Diuretics 6 (4.4) 6 (4.1) 0.880
β-Blocker 6 (4.4) 7 (4.8) 0.899
Calcium channel
blocker
30 (22.2) 11 (7.5) < 0.01
ACE inhibitor 1 (0.7) 1 (0.7) 0.729
Angiotensin II
receptor antagonist
32 (23.7) 25 (17.0) 0.162
Direct Renin Inhibitor 0.0 1 (0.7) 0.521
Platelet aggregation
inhibitor
9 (6.7) 16 (10.9) 0.213
Daily dosage of
atorvastatin
2.5 mg 1 (0.7) 0
5 mg 66 (48.9) 61 (41.5)
Table 1 Baseline characteristics of the study population
(Continued)
10 mg 68 (50.4) 82 (55.8) 0.224
15 mg 0 2 (1.4)
20 mg 0 1 (0.7)
30 mg 0 1 (0.7)
Duration of use of
atorvastatin prior to
index dateb
126 (10~332) 98 (14~229) < 0.05
Abbreviation: ACE angiotensin-converting enzyme.
aValues expressed as number (%) or median (range).
bValues of duration of use of atorvastatin prior to index date expressed
as days.
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A sensitivity analysis was conducted to assess differences
in adherence for patients who were “not adherent” at
baseline (PDC was < 80% in the pre-index date) in each
cohort. There was no significant difference in the propor-
tion of patients achieving adherence between the changed
and continued cohorts (adjusted OR = 1.00, 95% CI =
0.23–4.27). Persistence with therapy was not significantly
different (adjusted HR = 0.92, 95% CI = 0.38–2.19).
Discussion
This study suggested that medication adherence for pa-
tients newly treated with atorvastatin was not negatively
influenced by changing from a brand-name atorvastatin
to a generic product. In fact, there was no significant dif-
ference in the proportion of patients achieving adher-
ence between those changing to a generic drug and
those continuing with a brand-name drug. Furthermore,
there was no difference in the persistence with therapy
across the cohorts.
A number of generic statins were approved, and the
rate of changing to generic statins increased. Chapman
et al. [13] showed that therapeutic substitution patients,
who changed from a brand-name statin to a generic ver-
sion of a different statin, were 33% less likely to be ad-
herent compared with generic substitution patients, who
changed from a branded to a generic version of the same
statin at 6-month post-change. However, there are few
reports about adherence with changes from a brand-
name statin to a generic version of same statin com-
pared with continuing with the brand-name statin.
Gagne et al. [22] showed that patients treated with gen-
eric statins were more likely to adhere and had a lower
rate of composite clinical outcome compared with those
treated with brand-name version of same statin. This
discrepancy in adherence between our finding and this
study might be due to situations regarding the health in-
surance and socioeconomy in the United States and
Japan. The study cohort comprised Medicare beneficiar-
ies aged 65 years or older. Other potential reason for
Table 2 Proportion of days covered in pre- and post-index date for the changed and continued cohorts




PDC, %, median (range) 97.7 (34.1 ~ 100) 92.4 (22.9 ~ 100) <0.01
Patients achieving adherence (PDC≧80%) (number, (%)) 116 (85.9) 108 (73.5) < 0.05
Post-index date
PDC, %, median (range) 92.2 (7.8~100) 89.4 (15.6~100) 0.058
Patients achieving adherence (PDC≧80%) (number, (%)) 96 (71.1) 93 (63.3) 0.162 1.43 (0.87-2.36) 0.84 (0.46-1.52)
PDC difference from pre- to post-index date (%) - 8.6** - 10.3** 0.443
Median of proportion of days covered (PDC) and proportion of patients achieving adherence (PDC ≧ 80%) in the pre- and post-index date, and odds ratio of
achieving adherence (PDC ≧ 80%) for the changed and continued cohorts.
aLogistic regression model analysis.
bAdjusted baseline covariates included adherence in pre-index date (baseline adherence) (PDC≧80 %), duration of use of atorvastatin prior to index date, prescribing
medical establishment, and comorbidities, such as hypertension, arrhythmia, and calcium channel blocker.
**:Significant difference in PDC change from pre- to post-index date for the changed and continued cohorts (P < 0.01).
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taking into account changing from a brand-name to gen-
eric product, however the study compared patients initi-
ating generic statins with those initiating brand-name
products. For the treatment of hypertension, some stud-
ies [23,24] have compared changing to a generic substi-
tute with continuing brand-name drugs; these studies
showed that the generic substitution of an antihyperten-
sive drug did not lead to lower adherence. Our findings
were consistent with these studies. Studies about generic
substitution for new users who are therapeutic initiators,
but not prevalent users, are limited [23]. Prevalent users
who have been using statins for long time tend to be
healthier and more adherent to therapy and screening
than new users [15,25]. This phenomenon may result in
biased estimates of the effect of adherence. Thus, we ex-
























Figure 2 Difference in proportion of days covered (PDC) from
pre- to post-index date for the changed and continued cohorts.when changing from a brand-name statin to a generic
product of same statin adds to the literature.
Adherence to statin treatment was associated with
health outcomes, such as reduction in major vascular
events, lower cardiovascular morbidity and mortality
rates [9-11]. Our finding may imply that incidence of
health outcomes is not increased by the change from a
brand-name atorvastatin to a generic product. Thus,
changing to a generic product may have health benefits
in addition to the known cost benefits. Further research
is required to confirm the effect on health outcomes fol-
lowing the change to a generic product.
The PDC values were expressed as median and range
in our study. The mean PDC values in two cohorts
ranged from was 77.6% to 83.3% in the post-index date
(data not shown). These results differed from those of
Benner et al. [15] who found the mean PDC was 56%
after the first 6 months of statin treatment. This might
be due to a difference in the age of population. The pa-
tients in our study were middle-aged (mean age = 52),
whereas those in Benner et al. were elderly (mean age =
74 years). However, the persistence rate 6 months after
the index date fell to an average of 67.3% and 75.6%,
which is comparable to the study of Perreault et al. [26].
They found a 65% persistence rate in a group of middle-
age patients, also newly treated with statins, after the
first 6 months of treatment. Further research is required
to analyze whether various kinds of generic atorvastatin
affect patient adherence.
The limitations of this study include the potential for
the several forms of bias. Due to the retrospective and
non-randomized nature of the design, selection bias may
have resulted in more adherent patients in the changing
cohort at baseline. In the pre-index date, the proportion
of patients achieving adherence (PDC ≧ 80%) among the
Table 3 Persistence duration and associated hazard ratio for the changed and continued cohorts
Persistence durationa, days, median (range) Hazard ratiob(95 %CI)
Changed to generic Continued brand P value Unadjusted Adjustedc
180 (14~180) 180 (28~180) 0.076 0.69 (0.44-1.08) 0.97 (0.61-1.55)
aPersistence was measured as the number of continuous days from index date to discontinuation in the 180-day.
bCox proportional hazard model.
cAdjusted baseline covariates included adherence in pre-index date (baseline adherence) (PDC≧80 %), duration of use of atorvastatin prior to index date, prescribing
medical establishment, comorbidities such as hypertension, arrhythmia, and calcium channel blocker.
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cohort (85.9% vs 73.5%). These rates may be influenced
by physicians; physicians may not change patients from
a brand-name product to a generic product if the patient
has poor adherence, or it is assumed that a change
might negatively affect the treatment. However, the re-
sult of the sensitivity analysis for non-adherent patients
at baseline in the two cohorts found no significant differ-
ence in adherence. There were some differences in pa-
tient characteristics between the cohorts, including the
duration of use of atorvastatin prior to the index date,
prescribing medical establishment, and comorbidities,
such as hypertension, arrhythmia, and other medica-
tions, such as calcium channel blockers. Although there
may be covariates that we did not include, we adjusted
for the known covariates included baseline adherence in
pre-index date to reduce the influence of any bias.
Another limitation in our study may have introduced in-
formation bias. Analysis of adherence was based on phar-
macy dispensing records, and the actual medication taken
by the patients is unknown. This unknown may affect the
cohorts because it is probably non-differentially distrib-
uted between the two groups. However, most studies
using the validity of prescription rates have found that























Figure 3 Kaplan-Meier analysis of persistence with therapy for
the changed and continued cohorts. a: Time of follow up started
from index date.with clinical measures of adherence, serum drug levels, or
physiologic drug effects [27].
There were other potential confounding factors that
could not be considered in this insurance claim database
analysis. Information on adverse experiences and laboratory
tests was not available. Furthermore, medical counseling,
the patient’s beliefs about treatment, and the effects on clin-
ical end-points, such as measures of cholesterol, were not
included in the database. Although studies using informa-
tion from such databases can access information on many
patients gathered in real-world conditions, it is not possible
to assess the influence of these other factors. However, the
strengths of this study include the available factors related
to adherence, such as prescribed daily doses and diagnoses,
which minimized any confounding bias. Furthermore, the
claim database included few elderly patients. Therefore,
generalization of these results to elderly patients is limited.
Although generic products are not still fully covered in
Japan, patients are encouraged to accept changing from
a brand-name drug to a generic product from the per-
spective of adherence and cost.Conclusions
In conclusion, the results of this study suggest that chan-
ging from a brand-name atorvastatin to a generic product
does not lead to a decrease in adherence for patients
newly treated with atorvastatin. Therefore, changing to ge-
nerics for patients seems to be reasonable from the per-
spective of adherence to statin therapy and cost benefits.
Further investigation is required to confirm these results
with other types of medications for chronic conditions.
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